{"title":"转介到纤维扫描中心的慢性肝病病因学的变化:非酒精性脂肪性肝病的患病率增加。","authors":"Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz","doi":"10.14744/hf.2022.2022.0042","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan<sup>®</sup> is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan<sup>®</sup>.</p><p><strong>Materials and methods: </strong>Demographic characteristics, CLD etiologies, and FibroScan<sup>®</sup> parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.</p><p><strong>Results: </strong>Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18-88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.</p><p><strong>Conclusion: </strong>NAFLD was the most common indication for referral to FibroScan<sup>®</sup>.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/69/hf-4-007.PMC9951899.pdf","citationCount":"1","resultStr":"{\"title\":\"Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.\",\"authors\":\"Tansu Eris, Moomen Hassan, Yousra Hikal, Enas Sawah, Fatemeh Daneshgar, Ayse Gulsen Teker, Furkan Ozel, Nimet Emel Luleci, Eda Kaya, Yusuf Yilmaz\",\"doi\":\"10.14744/hf.2022.2022.0042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan<sup>®</sup> is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan<sup>®</sup>.</p><p><strong>Materials and methods: </strong>Demographic characteristics, CLD etiologies, and FibroScan<sup>®</sup> parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.</p><p><strong>Results: </strong>Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18-88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.</p><p><strong>Conclusion: </strong>NAFLD was the most common indication for referral to FibroScan<sup>®</sup>.</p>\",\"PeriodicalId\":29722,\"journal\":{\"name\":\"Hepatology Forum\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/69/hf-4-007.PMC9951899.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Forum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/hf.2022.2022.0042\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2022.2022.0042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease.
Background and aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. FibroScan® is used for follow-up of fibrosis and steatosis. This single-center study aims to review the distribution of indications by referral to FibroScan®.
Materials and methods: Demographic characteristics, CLD etiologies, and FibroScan® parameters of the patients who were referred to our tertiary care center between 2013 and 2021 were retrospectively evaluated.
Results: Out of 9345 patients, 4946 (52.93%) were males, and the median age was 48 [18-88] years. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N=4768, 51.02%), followed by hepatitis B (N=3194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age, sex, and CLD etiology, the results revealed that patients with older age (Odds ratio (OR)=2.908; confidence interval (CI)=2.597-3.256; p<0.001) and patients with hepatitis C (OR=2.582; CI=2.168-3.075; p<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, p<0.001), and autoimmune hepatitis (OR=2.138; CI=1.360-3.660, p<0.001) had increased odds of advanced liver fibrosis compared to NAFLD.
Conclusion: NAFLD was the most common indication for referral to FibroScan®.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
